RTW Biotech Opportunities Ltd - London-based venture capital firm focused on biotechnology companies - Says net asset value per share at January 31 was USD1.94, up 2.5% from USD1.90 the previous month. Notes that this NAV does not reflect the completion of the Arix Bioscience PLC transaction. RTW intends to publish, at the soonest opportunity, an indicative and estimated pro forma NAV and NAV per share reflecting the completion of the transaction and new share issuance. In January, RTW said it completed its previously announced acquisition of a 25.5% stake in Arix Bioscience PLC for USD57.1 million, equivalent to GBP1.37 per Arix share. Purchase is to support its planned all-share acquisition of Arix's assets.
Current stock price: 99.30 pence
12-month change: down 5.6%
By Jeremy Cutler, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2024 Alliance News Ltd. All Rights Reserved.
Rtw Biotech (RTW)